In our study, SLC7A5 was found to predict drug therapy response in BLCA, and It is possible that patients with higher SLC7A5 levels might respond better to EGFR-targeted treatment, radiotherapy, and chemotherapy drugs such as cisplatin, paclitaxel, bleomycin, docetaxel and vincristine. This evidence concerns the gene SLC7A5 and bladder transitional cell carcinoma.